

# Phase III randomised controlled trial of a breathlessness intervention service for intractable breathlessness

<b>Submission date</b> 30/10/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 18/12/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 24/01/2022	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

<http://www.cancerhelp.org.uk/trials/a-trial-looking-at-a-service-for-people-who-have-problems-with-breathlessness>

## Contact information

### Type(s)

Scientific

### Contact name

Mrs Jennifer Gray

### Contact details

Breathlessness Intervention Service  
Box 193 Palliative Care  
Addenbrooke's Hospital  
Cambridge University Hospital's NHS Foundation Trust  
Hills Road  
Cambridge  
United Kingdom  
CB2 0QQ

### Type(s)

Scientific

### Contact name

Dr Sara Booth

### Contact details

Addenbrooke's Hospital  
Cambridge University Hospitals NHS Foundation Trust  
Palliative Care Box 193  
Hills Road  
Cambridge  
United Kingdom  
CB2 0QQ

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT00678405

**Protocol serial number**  
v2 09/09/08

## Study information

### Scientific Title

Phase III randomised controlled trial of a breathlessness intervention service for intractable breathlessness

### Acronym

Phase III RCT BIS

### Study objectives

The aim of this study is to evaluate the impact of the Breathlessness Intervention Service (BIS) on the quality of life of patients and families affected by intractable breathlessness. The questions to be addressed by the research are:

1. Is BIS more effective than standard care for patients with intractable breathlessness from advanced malignant or non-malignant disease?
2. Does it reduce patient and carer distress due to breathlessness, and increase patients' sense of mastery of the symptom?
3. What are the experiences and views of those who use BIS, their informal carers and the clinicians who refer to it?
4. Is BIS cost-effective?

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Cambridgeshire 2 Research Ethics Committee, July 2008. Substantial amendment submitted in September 2008 and approved October 2008.

### Study design

Randomised controlled phase III (MRC's framework for complex interventions) parallel-assignment single-blind (investigator) trial

### Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Intractable breathlessness, malignant and non-malignant conditions

## Interventions

Active comparator:

Waiting list groups (malignant and non-malignant) - best supportive care (standard care).

Standard care entails specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology), which may include specialist nurse input, and primary care services.

Experimental:

Fast-track (malignant and non-malignant) Breathlessness Intervention Service. The Breathlessness Intervention Service consists of a clinical specialist physiotherapist and palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence based non-pharmacological interventions (psychological, social and physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns) and pharmacological review. BIS seeks to enhance the self-management of breathlessness. The treatment is holistic in nature in that it is located in clinic or in patient's home as appropriate. Referrals come from medical specialists, GPs and allied health professionals.

The two broad disease courses, malignant and non-malignant, will be considered separately due to their different trajectories and needs, and resultant different service models. The intervention model for patients with non-malignant disease consists of two - three visits and three telephone contacts (to patient and/or primary care staff) over a four-week period with a 16 week (from first assessment) follow-up, whereas the model for patients with malignant disease consists of one visit in conjunction with a primary care professional/key worker and two telephone contacts (to patient and/or primary care staff/key worker) over a two-week period, with a six week (from first assessment) follow-up. Thus, the measurement points for the disease groups will differ.

Timepoints for non-malignant group:

Fast-track group: after baseline interview (t1), the fast-track group will receive BIS for four weeks. The next measurement (nmFTt2) will be conducted midway through the intervention (2 weeks post-commencing BIS), then again after discharge from BIS (nmFTt3) and finally 4 weeks after discharge from BIS (nmFTt5).

Waiting list group: after baseline interview (t1), the waiting list group will receive standard care for four weeks, then will receive the BIS intervention for another four weeks. Interviews will be held 2 weeks from entering the waiting list group (nmCct2), prior to commencing BIS (nmCct3), during BIS (two weeks post-commencing BIS; nmCct4) and then again after discharge from BIS (four weeks post-commencing BIS (nmCct5).

Timepoints for malignant group:

Fast-track group: after baseline interview (t1), the fast-track group will receive BIS for two weeks. The measures will be repeated after discharge from BIS (two weeks post-commencement of BIS; mFTt3) and then again two weeks after discharge (mFTt5).

Waiting list group: after baseline interview (t1), the waiting list group will receive standard care for two weeks, then will receive the BIS intervention for another two weeks. Measures will be repeated just prior to commencing BIS (mCCT3) and then again after discharge on from BIS (two weeks post-commencing BIS, mCCT5).

## **Intervention Type**

Other

## **Phase**

Phase III

## **Primary outcome(s)**

Numerical Rating Scale (NRS) distress due to breathlessness.

Time Frame:

Malignant group: 2 weeks after baseline

Non-malignant group: 4 weeks after baseline

## **Key secondary outcome(s)**

1. Modified Borg
2. NRS breathlessness at best/worst/average
3. Dyspnoea descriptors (patients only)
4. A wellbeing measure
5. Chronic Respiratory Questionnaire (CRQ - patients only)
6. EQ-5D (EuroQoL)
7. Hospital Anxiety Depression Scale
8. Client Service Receipt Inventory
9. Charlton Co-morbidity Index
10. Social functioning item
11. Karnofsky Performance Scale
12. Burden Interview and Caregiver appraisal scale (carer only)
13. Experience of breathlessness and expectations of/views/satisfaction with BIS (qualitative)

Time Frame:

Malignant group: 2 weeks after baseline

Non-malignant group: 4 weeks after baseline

## **Completion date**

30/04/2011

## **Eligibility**

### **Key inclusion criteria**

For patients:

1. Appropriate referral to BIS
2. Aged 18 years or older, either sex
3. Any patient not meeting any exclusion criteria

For carers:

1. Informal carers (significant others, relatives, friends or neighbours) of phase III recruits
2. Aged 18 years or older, either sex
3. Any carer not meeting any exclusion criteria

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

Patients/carers:

1. Unable to give informed consent
2. Previously used BIS
3. Demented/confused
4. Learning difficulties
5. Other vulnerable groups for example head injury, severe trauma, mental illness
6. Not meeting all inclusion criteria

**Date of first enrolment**

01/08/2008

**Date of final enrolment**

30/04/2011

**Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Addenbrooke's Hospital**

Cambridge

United Kingdom

CB2 0QQ

# Sponsor information

## Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

## ROR

<https://ror.org/04v54gj93>

# Funder(s)

## Funder type

Government

## Funder Name

National Institute for Health Research- Research for Patient Benefit (RfPB) programme (ref: PB-PG-0107-11134)

## Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

## Funding Body Type

Government organisation

## Funding Body Subtype

National government

## Location

United Kingdom

# Results and Publications

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	31/10/2014		Yes	No

<a href="#">Results article</a>	results	04/04/2016	Yes	No	
<a href="#">Protocol article</a>	protocol	20/05/2011	Yes	No	
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Plain English results</a>			24/01/2022	No	Yes